UCSC Human Gene Sorter
 
genome assembly search
sort by display output 
#
Name
VisiGene
BLASTP
E-Value
Genome Position
Description
1C1QAn/a
n/a
n/a
n/a
2e-126chr1 22,638,153complement C1q A chain, transcript variant 1 (from RefSeq NM_015991.4)
2C1QCn/a
n/a
n/a
n/a
5e-23chr1 22,645,870complement C1q C chain, transcript variant 2 (from RefSeq NM_172369.5)
3C1QBn/a
n/a
n/a
n/a
1e-26chr1 22,657,436complement C1q B chain, transcript variant 2 (from RefSeq NM_001378156.1)
4STAB1n/a
n/a
n/a
n/a
n/achr3 52,509,916stabilin 1 (from RefSeq NM_015136.3)
5IGHG3n/a
n/a
n/a
n/a
n/achr14 105,767,954immunoglobulin heavy constant gamma 3 (G3m marker) (from HGNC IGHG3)
6HYAL2n/a
n/a
n/a
n/a
n/achr3 50,320,276hyaluronidase 2, transcript variant 1 (from RefSeq NM_003773.5)
7CD68n/a
n/a
n/a
n/a
n/achr17 7,580,874CD68 molecule, transcript variant 1 (from RefSeq NM_001251.3)
8ENSG00000264772n/a
n/a
n/a
n/a
n/achr17 7,577,425ENSG00000264772 (from geneSymbol)
9IGHG4n/a
n/a
n/a
n/a
n/achr14 105,623,286Constant region of immunoglobulin heavy chains.  Immunoglobulins, also known as antibodies, are membrane-bound or  secreted glycoproteins produced by B lymphocytes. In the recognition  phase of humoral immunity, the membrane-bound immunoglobulins serve as  receptors which, upon binding of a specific antigen, trigger the clonal  expansion and differentiation of B lymphocytes into immunoglobulins-  secreting plasma cells. Secreted immunoglobulins mediate the effector  phase of humoral immunity, which results in the elimination of bound  antigens (PubMed:22158414, PubMed:20176268). The antigen binding site  is formed by the variable domain of one heavy chain, together with that  of its associated light chain. Thus, each immunoglobulin has two  antigen binding sites with remarkable affinity for a particular  antigen. The variable domains are assembled by a process called V-(D)-J  rearrangement and can then be subjected to somatic hypermutations  which, after exposure to antigen and selection, allow affinity  maturation for a particular antigen (PubMed:17576170, PubMed:20176268). (from UniProt P01861)
10HLA-DPB1n/a
n/a
n/a
n/a
n/achr6 33,082,843major histocompatibility complex, class II, DP beta 1 (from RefSeq NM_002121.6)
11HMOX1n/a
n/a
n/a
n/a
n/achr22 35,387,651heme oxygenase 1 (from RefSeq NM_002133.3)
12HLA-DMAn/a
n/a
n/a
n/a
n/achr6 32,950,857major histocompatibility complex, class II, DM alpha (from RefSeq NM_006120.4)
13TM4SF1n/a
n/a
n/a
n/a
n/achr3 149,373,335transmembrane 4 L six family member 1, transcript variant 1 (from RefSeq NM_014220.3)
14PTPN12n/a
n/a
n/a
n/a
n/achr7 77,588,682protein tyrosine phosphatase non-receptor type 12, transcript variant 1 (from RefSeq NM_002835.4)
15LRRC32n/a
n/a
n/a
n/a
n/achr11 76,664,135leucine rich repeat containing 32, transcript variant 6 (from RefSeq NM_001370190.1)
16IGHG2n/a
    
    
     
n/achr14 105,642,174Constant region of immunoglobulin heavy chains.  Immunoglobulins, also known as antibodies, are membrane-bound or  secreted glycoproteins produced by B lymphocytes. In the recognition  phase of humoral immunity, the membrane-bound immunoglobulins serve as  receptors which, upon binding of a specific antigen, trigger the clonal  expansion and differentiation of B lymphocytes into immunoglobulins-  secreting plasma cells. Secreted immunoglobulins mediate the effector  phase of humoral immunity, which results in the elimination of bound  antigens (PubMed:22158414, PubMed:20176268). The antigen binding site  is formed by the variable domain of one heavy chain, together with that  of its associated light chain. Thus, each immunoglobulin has two  antigen binding sites with remarkable affinity for a particular  antigen. The variable domains are assembled by a process called V-(D)-J  rearrangement and can then be subjected to somatic hypermutations  which, after exposure to antigen and selection, allow affinity  maturation for a particular antigen (PubMed:17576170, PubMed:20176268). (from UniProt P01859)
17COPDA1n/a
n/a
n/a
n/a
n/achr14 105,648,490COPDA1 (from geneSymbol)
18ECE1n/a
n/a
n/a
n/a
n/achr1 21,253,856endothelin converting enzyme 1, transcript variant 1 (from RefSeq NM_001397.3)
19PLOD3n/a
n/a
n/a
n/a
n/achr7 101,211,782procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 (from RefSeq NM_001084.5)
20LEPROTn/a
n/a
n/a
n/a
n/achr1 65,428,337leptin receptor overlapping transcript, transcript variant 1 (from RefSeq NM_017526.5)
21SNX9n/a
n/a
n/a
n/a
n/achr6 157,884,161sorting nexin 9 (from RefSeq NM_016224.5)
22GSDMDn/a
n/a
n/a
n/a
n/achr8 143,560,704gasdermin D, transcript variant 1 (from RefSeq NM_024736.7)
23HSD17B11n/a
n/a
n/a
n/a
n/achr4 87,363,851hydroxysteroid 17-beta dehydrogenase 11 (from RefSeq NM_016245.5)
24ENSG00000255723n/a
n/a
n/a
n/a
n/achr4 87,331,190ENSG00000255723 (from geneSymbol)
25TMEM204n/a
n/a
n/a
n/a
n/achr16 1,544,617transmembrane protein 204, transcript variant 1 (from RefSeq NM_024600.6)
26ARPC1B27999
n/a
n/a
n/a
n/achr7 99,384,773actin related protein 2/3 complex subunit 1B (from RefSeq NM_005720.4)
27ENSG00000284292n/a
n/a
n/a
n/a
n/achr7 99,360,266Cytoplasm, cytoskeleton   Nucleus (from UniProt A0A1W2PNV4)
28IL6STn/a
n/a
n/a
n/a
n/achr5 55,965,029interleukin 6 cytokine family signal transducer, transcript variant 4 (from RefSeq NR_120480.2)
29STING1n/a
n/a
n/a
n/a
n/achr5 139,479,145stimulator of interferon response cGAMP interactor 1, transcript variant 1 (from RefSeq NM_198282.4)
30MAP3K11n/a
n/a
n/a
n/a
n/achr11 65,605,989mitogen-activated protein kinase kinase kinase 11 (from RefSeq NM_002419.4)
31ENSG00000272234n/a
    
    
     
n/achr5 42,806,695ENSG00000272234 (from geneSymbol)
32ENSG00000261684n/a
n/a
n/a
n/a
n/achr15 42,514,737ENSG00000261684 (from geneSymbol)
33VSIG4n/a
n/a
n/a
n/a
n/achrX 66,030,909V-set and immunoglobulin domain containing 4, transcript variant 1 (from RefSeq NM_007268.3)
34SLC39A1n/a
n/a
n/a
n/a
n/achr1 153,961,323solute carrier family 39 member 1, transcript variant 3 (from RefSeq NM_001271958.2)
35ENSG00000285779n/a
n/a
n/a
n/a
n/achr1 153,967,519ENSG00000285779 (from geneSymbol)
36LYVE1n/a
n/a
n/a
n/a
n/achr11 10,562,815lymphatic vessel endothelial hyaluronan receptor 1 (from RefSeq NM_006691.4)
37CORO1Bn/a
n/a
n/a
n/a
n/achr11 67,439,493coronin 1B, transcript variant 1 (from RefSeq NM_020441.3)
38CAVIN2n/a
    
    
     
n/achr2 191,840,699caveolae associated protein 2 (from RefSeq NM_004657.6)
39TINAGL1n/a
n/a
n/a
n/a
n/achr1 31,582,100tubulointerstitial nephritis antigen like 1, transcript variant 1 (from RefSeq NM_022164.3)
40LINC01226n/a
n/a
n/a
n/a
n/achr1 31,544,790long intergenic non-protein coding RNA 1226 (from HGNC LINC01226)
41COLGALT129536
n/a
n/a
n/a
n/achr19 17,569,403collagen beta(1-O)galactosyltransferase 1 (from RefSeq NM_024656.4)
42KCTD12n/a
n/a
n/a
n/a
n/achr13 76,883,290potassium channel tetramerization domain containing 12 (from RefSeq NM_138444.4)
43UBA7n/a
n/a
n/a
n/a
n/achr3 49,809,581ubiquitin like modifier activating enzyme 7 (from RefSeq NM_003335.3)
44MIR5193n/a
n/a
n/a
n/a
n/achr3 49,806,191microRNA 5193 (from RefSeq NR_049825.1)
45RETSATn/a
n/a
n/a
n/a
n/achr2 85,348,241retinol saturase (from RefSeq NM_017750.4)
46ENSG00000285641n/a
n/a
n/a
n/a
n/achr1 153,981,048ENSG00000285641 (from geneSymbol)
47RAMP3n/a
n/a
n/a
n/a
n/achr7 45,171,020receptor activity modifying protein 3 (from RefSeq NM_005856.3)
48MAFKn/a
n/a
n/a
n/a
n/achr7 1,536,872MAF bZIP transcription factor K (from RefSeq NM_002360.4)
49RAMP2n/a
n/a
n/a
n/a
n/achr17 42,762,134receptor activity modifying protein 2 (from RefSeq NM_005854.3)
50GNSn/a
n/a
n/a
n/a
n/achr12 64,736,427glucosamine (N-acetyl)-6-sulfatase (from RefSeq NM_002076.4)